Common and rare variants in complement genes as biomarkers of COVID-19 infection and severity. A lesson to learn for emerging pathogens - Scorecard - MDSpire

Common and rare variants in complement genes as biomarkers of COVID-19 infection and severity. A lesson to learn for emerging pathogens

  • By

  • María Eugenia De La Morena-Barrio

  • Ana Van Den Rym

  • Olga Escorial Sanz

  • Fernando Corvillo

  • Rosario García-Sánchez

  • Laura González-Sánchez

  • Adrián Muñoz-Barrera

  • Rafaela González-Montelongo

  • José Miguel Lorenzo-Salazar

  • Carlos Flores

  • Ana de Andrés-Martín

  • Carlos Rodríguez-Gallego

  • Luis Allende

  • Laia Alsina

  • Silvia Sánchez-Ramón

  • Eduardo López-Collazo

  • Margarita López-Trascasa

  • Pilar Sánchez-Corral

  • Rebeca Pérez de Diego

  • Javier Corral de la Calle

  • Alberto López-Lera

  • June 11, 2026

  • 0 min

Share

Clinical Scorecard: Genetic Variants in Complement Pathway Genes as Indicators of COVID-19 Infection and Severity: Insights for Future Pathogen Responses

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationAdults hospitalized due to severe COVID-19, aged 18 and older.
Care Setting

Key Highlights

  • CFHR4 rs7417769 and CFH rs1061170 polymorphisms associated with protection against ARDS; specify their mechanisms.
  • C3 rs2230199 and MASP2 rs7255087 polymorphisms correlated with C3 levels; clarify their clinical relevance.
  • Defective complement activation linked to increased SARS-CoV-2 infection rates; provide context on how this affects patient outcomes.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider genetic biomarkers for risk assessment in COVID-19 severity; specify which tests to use.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Genetic variants may inform treatment strategies and risk stratification; detail how this can be applied in practice.

        Clinical Best Practices

        • Utilize genetic testing for complement pathway variants in severe COVID-19 cases; include supporting evidence.
        • Assess complement activation levels in patients with ARDS; provide rationale for this practice.

        Related Resources & Content

        Original Source(s)

        Common and rare variants in complement genes as biomarkers of COVID-19 infection and severity. A lesson to learn for emerging pathogens

        • by María Eugenia De La Morena-Barrio, Ana Van Den Rym, Olga Escorial Sanz, Fernando Corvillo, Rosario García-Sánchez, Laura González-Sánchez, Adrián Muñoz-Barrera, Rafaela González-Montelongo, José Miguel Lorenzo-Salazar, Carlos Flores, Ana de Andrés-Martín, Carlos Rodríguez-Gallego, Luis Allende, Laia Alsina, Silvia Sánchez-Ramón, Eduardo López-Collazo, Margarita López-Trascasa, Pilar Sánchez-Corral, Rebeca Pérez de Diego, Javier Corral de la Calle, Alberto López-Lera

        • June 11, 2026

        Related Content

        The CRISPR-powered Diagnostic SLEUTH

        Novel DNA-guided system may support future RNA diagnostics and mutation detection

        • May 22, 2026

        • 2 min
        The latest developments on Ebola, hepatitis B, long Covid

        Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates